Ken Griffin Autolus Therapeutics PLC Put Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024
BUY
$5.39 - $7.29 $23,177 - $31,347
4,300 Added 130.3%
7,600 $48,000
Q4 2023

Feb 14, 2024
BUY
$2.13 - $6.63 $7,029 - $21,879
3,300 New
3,300 $21,000
Q2 2023

Aug 14, 2023
SELL
$1.64 - $3.21 $491 - $963
-300 Reduced 4.11%
7,000 $16,000
Q1 2023

May 15, 2023
BUY
$1.75 - $2.25 $9,975 - $12,825
5,700 Added 356.25%
7,300 $13,000
Q4 2022

Feb 14, 2023
BUY
$1.74 - $3.25 $2,784 - $5,200
1,600 New
1,600 $3,000

Others Institutions Holding AUTL

# of Institutions
123
Shares Held
168M
Call Options Held
411K
Put Options Held
67.6K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $316M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email